215
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Original Paper: The management of Helicobacter pylori infection in primary care Guidelines from the ESPCG

, , , &
Pages 98-104 | Received 29 Apr 1999, Accepted 02 Aug 1999, Published online: 11 Jul 2009
 

Abstract

Objective: There have been numerous national and international attempts to define the management of H. pylori infection, largely characterised by a consensus approach and a predominantly specialist perspective. Most patients with H. pylori infection are managed in primary care where the approach is patient centred and often symptom based. The aim of this project was to develop evidence-based guidelines that were relevant and valid for general practitioners (GPs) across all of Europe.

Method: A consensus meeting of 48 GPs from nine European countries identified key issues through the structured consideration in small groups of a series of case scenarios. The process was supported by access to national prevalence data, key research literature and on-line databases. It featured an immediate and a later postal feedback round. Consensus scores were calculated for each decision point, together with a rating of the supporting evidence. The output was combined with a systematic review of the literature.

Results: The key guidance points are as follows: 1) Eradication therapy should be considered for patients who consult with recurrent dyspepsia, those with newly diagnosed peptic ulcer disease (PUD), and those with a previous diagnosis of PUD whose symptoms relapse or who require long-term acid suppression therapy. 2) Carbon-13 urea breath test (CUBT) or endoscopy and biopsy are the recommended diagnostic tests for H. pylori infection. CUBT is the most useful test for successful eradication. 3) The recommended eradication therapy is a standard dose of proton pump inhibitor, clarithromycin 500 mg and amoxycillin 1000 mg, all twice daily for seven days. 4) An awareness of local resistance rates for metronidazole and clarithromycin is essential for effective treatment.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.